文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study.

作者信息

Higué Jules, Orvain Corentin, Dumas Pierre-Yves, Peterlin Pierre, Hospital Marie-Anne, Barrière Sabrina, Couturier Audrey, Carre Martin, Chantzi Areti, Tavernier Emmanuelle, Delabesse Éric, Bidet Audrey, Bouvier Anne, Mozziconacci Marie-Joelle, Véronèse Lauren, Pastoret Cédric, Tondeur Sylvie, Flandrin-Gresta Pascale, Lachot Sébastien, Cazaux Marine, Thépot Sylvain, Forcade Edouard, Chevallier Patrice, Devillier Raynier, Aspas Requena Gaspar, Bertoli Sarah, Pigneux Arnaud, Récher Christian

机构信息

Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université de Toulouse, Toulouse, France.

Maladies du Sang, Centre Hospitalier Universitaire d'Angers, Angers, France.

出版信息

Blood Cancer J. 2025 Aug 21;15(1):141. doi: 10.1038/s41408-025-01344-3.

DOI:10.1038/s41408-025-01344-3
PMID:40841520
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12371059/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3321/12371059/4ab2f028adb2/41408_2025_1344_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3321/12371059/4ab2f028adb2/41408_2025_1344_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3321/12371059/4ab2f028adb2/41408_2025_1344_Fig1_HTML.jpg

相似文献

[1]
Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study.

Blood Cancer J. 2025-8-21

[2]
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML.

Ann Hematol. 2025-7-9

[3]
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS.

Blood Neoplasia. 2024-5-23

[4]
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.

Blood Adv. 2021-3-9

[5]
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.

Lancet Haematol. 2024-4

[6]
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.

Hematol Oncol. 2024-5

[7]
Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.

Future Oncol. 2023-4

[8]
Venetoclax plus azacitidine as genetic-driven bridge-to-transplant therapy for IDH2-mutated acute myeloid leukaemia (AML) refractory to intensive chemotherapy: proof-of-concept case reports.

Ann Hematol. 2025-7-8

[9]
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed -Mutated or -Rearranged AML.

J Clin Oncol. 2025-8-10

[10]
Safety and Efficacy of Grapefruit Juice Combined With Low-Dose Venetoclax in AML Patients Ineligible for Intensive Chemotherapy.

Clin Ther. 2025-8

本文引用的文献

[1]
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials.

Lancet Haematol. 2025-5

[2]
Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study.

Leukemia. 2024-9

[3]
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).

J Clin Oncol. 2024-6-20

[4]
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.

Blood Adv. 2024-1-23

[5]
How I treat refractory and relapsed acute myeloid leukemia.

Blood. 2024-1-4

[6]
Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia.

Blood Cancer J. 2023-10-11

[7]
Acute myeloid leukaemia.

Lancet. 2023-6-17

[8]
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML.

Blood Adv. 2023-3-28

[9]
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.

Blood. 2022-9-22

[10]
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.

Blood. 2021-12-30

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索